Anti-Snoring Research

Graphical Representation of Data

Health status of the participants

The Good Sleep Project

The Good Sleep Project

Research Methods

The evaluation of the novel anti-snoring product was conducted over a six-month period, from January 21 to July 20, 2026. Testing was executed across two distinct geographical locations: Leeds, United Kingdom, and Larnaca, Cyprus. The research deliberately targeted individuals exhibiting loud snoring or diagnosed obstructive sleep apnoea. All the participants were in a relationship with a non-snoring partner. The participants maintained their habitual diet, exercise routines, and lifestyle behaviours throughout the evaluation period.

A mixed-methods empirical framework was deployed, building upon established research in obstructive sleep apnoea (OSA) and severe snoring. Qualitative data were gathered via structured, in-depth interviews assessing the psychological, emotional, and physical impacts of sleep deprivation on both snoring individuals and their non-snoring partners. Concurrently, quantitative sound telemetry was captured using calibrated decibel meters paired with daily observational logs maintained by the non-snoring partners.

Daily user trials were conducted to evaluate product efficacy and physiological tolerance. To ensure data integrity, the study monitored and accounted for three primary categories of confounding variables:

• Environmental Factors: Geographical location, microclimate, relative humidity, ambient temperature extremes, and ambient light exposure.

• Dietary Profiles: Lipid content, standardized hydration volumes, alcohol consumption, and the usage of standard or strong analgesics.

• Participant Health Status: Fluctuations in baseline health, tracking variance from asymptomatic periods to instances of acute upper respiratory tract irritation (e.g., mild rhinitis).

Participant Demographics and Research Limitations

Research cohorts were strictly stratified based on Body Mass Index (BMI) metrics (Weight Kg/ Height x Height). The investigation was restricted to three specific BMI categories:

• Overweight (Low-range, Slightly overweight): Mean BMI of 26.7 (comprising 5% of total participants).

• Overweight (High-range): Mean BMI of 29.8 (comprising 15% of total participants).

• Obesity Class 1: Mean BMI of 34.6 (comprising 80% of total participants).

The charts below show the health status and BMI of our participants.

How the research was conducted

Consequently, the efficacy and safety profile of this product have not been evaluated for individuals categorised under Obesity Class 2 or Obesity Class 3.

The applicability of these findings to those clinical cohorts remains unknown and falls outside the scope of this phase of research.

Furthermore, the study did not evaluate the confounding effects of alcohol consumption exceeding 24 grams per day. Because intake above this threshold is widely documented to cause severe adverse health outcomes, the scope of this research was strictly restricted to light and moderate consumption ranges.

Results of the research

Under specific health conditions, loud snoring temporarily recurred. This baseline shift was observed following the administration of strong analgesics, or during acute upper respiratory infections (e.g., common cold or influenza) where heavy mucus obstructed the airways. Snoring ceased once the medication cleared or the illness resolved. Given that adults average two to three colds annually—each lasting one to two weeks—this temporary return of snoring accounts for an estimated two to six weeks per year. 

The graphical data provides clear insight into the efficacy of the anti-snoring product across different user demographics. Figure 1 illustrates the average snoring noise levels (dB) over a 24-hour period for Group 1 (Slightly Overweight), while Figures 2 and 3 display the results for Group 2 (Overweight) and Group 3 (Class 1 Obesity), respectively. Each chart utilises the uppermost data series to establish the baseline snoring intensity prior to treatment. As shown in Figure 1, the baseline noise level for the slightly overweight group was 70 decibels (dB). Following the introduction of the anti-snoring product, noise levels decreased significantly to an average of 14 dB—a threshold comparable to normal respiration and clinically acceptable as near-silence. However, during periods of rhinovirus or influenza infection, data indicate a recurrence of loud snoring, reaching 56 to 61 dB depending on the specific group. While this range is comparable to normal conversational speech, a 60 dB ambient noise level remains disruptive to sleep hygiene. Regarding pharmacological factors, non-prescription analgesics (such as paracetamol, ibuprofen, and aspirin) demonstrated no significant impact on snoring volume. Conversely, central nervous system-depressing medications (e.g., tramadol and codeine) correlated with an increase in snoring intensity up to 60 dB. Finally, the anti-snoring product maintained high efficacy despite external dietary factors, with snoring volume remaining moderate following the consumption of high-fat foods and alcohol.

Figures 4, 5, and 6 present the average results for each treatment group over the 180-day evaluation period for the new anti-snoring product. Performance is quantified by the frequency of days categorized by snoring noise levels in decibels (dB). The primary upper bar illustrates the number of days classified as snoring-free or near-snoring-free, while subsequent bars delineate days with varying degrees of acoustic intensity. Proportional distributions are further detailed in Figures 7, 8, and 9, where pie charts illustrate the percentage of the 180-day period spent within specific decibel ranges for the participants.

1. Trial Overview and Efficacy
Trials for the anti-snoring product were conducted across test sites in Cyprus and the United Kingdom between 21 January and 20 July 2026. The product demonstrated high efficacy, with 89% of participants reporting improved sleep quality. Partners of the participants also reported enhanced sleep quality alongside a measurable reduction in anxiety regarding the health risks of heavy snoring.

2. Environmental and Behavioural Variables
The reduction in snoring frequency and volume remained consistent across both geographical testing regions. Furthermore, efficacy was sustained during targeted stress-testing, which evaluated participants following alcohol[**] consumption and a high-fat diet; audio recordings confirmed that snoring decibels remained significantly lower than baseline measurements under these conditions. Consequently, non-snoring partners experienced uninterrupted sleep cycles.

3. Participant Cohort Selection
The research deliberately targeted individuals exhibiting loud snoring or diagnosed obstructive sleep apnoea. All the participants were in a relationship with a non-snoring partner. While a subset of the population suffers from fatigue induced by "silent" sleep apnoea—often leaving partners undisturbed—this study focused strictly on loud snorers due to the established clinical correlation between high-decibel snoring and severe airway obstruction.

4. Secondary Quality-of-Life Outcomes
Longitudinal tracking of the participant couples indicated substantial improvements in relationship dynamics, driven by sleep restoration and reduced nocturnal disruption. Follow-up surveys highlighted several key secondary benefits:

• Interpersonal: Increased patience and lowered irritability between partners.

• Occupational: Elevated daytime energy levels and workplace productivity.

• Safety: Improved daytime alertness, resulting in a self-reported reduction in risks associated with drowsy driving.

While this research does not establish a direct causal link between snoring cessation and blood pressure reduction, extensive existing literature firmly connects severe snoring to hypertension. Accordingly, clinical consensus indicates that managing snoring serves as an effective strategy to mitigate elevated blood pressure.

Nocturnal Dipping Fails: In healthy people, blood pressure drops naturally by 10% to 20% at night to let the heart rest. In severe snorers, blood pressure stays elevated all night. Over time, this chronic stress damages the arteries and causes permanent high blood pressure during waking hours (Sleep and Sinus Centers of Georgia).

** The research did not evaluate the confounding effects of alcohol consumption exceeding 24 grams per day. Because intake above this threshold is widely documented to cause severe adverse health outcomes, the scope of this research was strictly restricted to light and moderate consumption ranges.